# An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

> **NCT07117630** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** L-Ornithine L-Aspartate
- **DRUG:** CDK4/6 inhibitor
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT07117630
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-25
- **Primary completion:** 2026-08
- **Final completion:** 2027-08
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07117630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07117630, "An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07117630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*